2014 Faculty Senate Awards

Transcription

1 2014 Faculty Senate Awards Mission College of Pharmacy Research Award Nominee Name: Jon Furuno Phone: Department: FA.OSU/OHSU College of Pharmacy Nomination Submissions and Required Documents Included in Packet 1. Nomination Letters 1 a. Jessina McGregor 2. Summary 3. CV 4. Letter of Support - 1 a. External - Daniel Diekema, University of Iowa Carver College of Medicine b. External Anthony Harris, University of Maryland

2 Faculty Senate Awards I am writing this letter to nominate Dr. Jon Furuno for the OHSU Faculty Senate s Research award. Before joining the OSU/OHSU College of Pharmacy, Dr. Furuno was a member of the faculty of the University of Maryland School of Medicine for six years. In the three years since joining our College, he has rapidly established a new research program examining antibiotic use in hospice and palliative care settings that includes strong collaborations with OHSU faculty both inside and outside of our College. This work has led to two presentations at local and regional professional meetings and an upcoming oral abstract presentation at the American Academy of Hospice and Palliative Medicine/Hospice and Palliative Nurses Association Annual Assembly meeting. To date, Dr. Furuno has 75 peer-reviewed journal publications; seven of which represent new work initiated after joining the College of Pharmacy. While at the University of Maryland, Dr. Furuno served as PI or Co-I on five federal awards and three industry funded wards. In addition to the two federally funded projects he transferred with him, Dr. Furuno has been awarded two new industry-sponsored, investigator-initiated grants since coming to Portland. Further, he is funded for his role on the Oregon Drug-Resistant Organism Prevention and Coordinated Regional Epidemiology (DROP-CRE) Network Advisory Committee, an organization based out of the Oregon Health Authority. His work on the DROP-CRE Network Advisory Committee has led to one publication and two regional professional presentations. In summary Dr. Furuno has had an incredibly productive research career to date and, since joining the College of Pharmacy, this trajectory continues. Hence I fully support Dr. Furuno as a candidate for the Research award. Jessina McGregor mcgregoj@ohsu.edu

3 ABBREVIATED CURRICULUM VITAE FOR OHSU RESARCH AWARD Jon P. Furuno, Ph.D. Associate Professor, Department of Pharmacy Practice Oregon State University/Oregon Health & Science University College of Pharmacy Last Updated February 18, 2014 Selected National Administrative Service (Within Past 5 Years) 6/01/08-6/30/16 Editorial Board, Infection Control and Hospital Epidemiology 6/01/09-present Associate Editor, BMC Public Health 2010 Mail Grant Reviewer, Recovery Act Limited Competition: Comparative Effectiveness Research on Upper Endoscopy in Gastroesophageal Reflux Disease (GERD), Eradication Methods for Methicillin Resistant Staphylococcus aureus (MRSA), and Dementia Detection and Management Strategies (RC4) 2010 Grant Reviewer, American Institute of Biological Sciences (Reston, VA) 2010 Grant Reviewer, PA Dept of Health Master Tobacco Settlement Research Projects present Member, SHEA Committee on Public Policy and Government Affairs 2012 Abstract Reviewer, Health Services, 45th Annual Society for Epidemiologic Research Meeting 2012 Annual Meeting Scientific Program Proposal Reviewer, 2013 American Geriatrics Society 2013-present Member, SIDP Research Awards Committee 2013-present Oregon State Health Care Acquired Infection Advisory Committee 2013-present Chair-elect, AAHPM Research Special Interest Group Selected Grant and Contract Support (Within Past 5 Years) 8/01/13-7/31/14 Co-Investigator (10% effort) Contract Number: 5U50C HAI Regional Multidrug-Resistant Organism Prevention and Detection Centers for Disease Control and Prevention/Oregon Health Authority Annual Direct Costs: $15,691 Total Direct Costs: $15,691 11/08/13-11/07/15 Principal Investigator (5% effort) IIR Risk Factors and Outcomes of Complicated Intra-abdominal Infections Cubist Pharmaceuticals, Inc. Annual Direct Costs: $58,986 Total Direct Costs: $58,986 11/08/13-11/07/15 Co-Investigator (5% effort) IIR Risk factors for complicated UTI due to Pseudomonas aeruginosa Cubist Pharmaceuticals, Inc. Annual Direct Costs: $59,662 Total Direct Costs: $59,662 2/1/14-1/31/16 Co-investigator (2% effort)

4 J.P. Furuno, page 2 February Sojourns Award- No Number Envisioning Sustainable Palliative Cancer Care Cambia Health Foundation Annual Direct Costs: $5,068 Total Direct Costs: $10,136 7/27/10-7/26/12 Co-Investigator (25% effort)* Contract Number: HHSA Using Nursing Home Antibiograms to Improve Antibiotic Prescribing and Delivery Agency for Healthcare Research and Quality Annual Direct Costs: $222,137 Total Direct Costs: $444,775 *Relinquished title of PI when changed institutions. 2/15/08-1/31/13 Principal Investigator (75% effort) Grant Number: 1K01AI Epidemiology of resistant bacteria in acute-care and long-term care facilities National Institutes of Health, National Institute for Allergy and Infectious Diseases Annual Direct Costs: $131,420 Total Direct Costs: $610,843 8/01/12-7/31/13 Co-Investigator (15% effort) Contract Number: CDC101203PPHF12 Regional Multidrug-Resistant Organism Prevention and Detection Centers for Disease Control and Prevention/Oregon Health Authority Annual Direct Costs: $21,144 Total Direct Costs: $21,144 Selected Peer Reviewed Publications (38 published in the last 5 years, 75 overall) 1. Furuno JP, Kaye KS, Malani PN, Mody L. Implementing long-term care infection control guidelines into practice: a case-based approach. Annals of Long-Term Care: Clinical Care and Aging. 2010;28(2): Furuno JP, Shurland SM, Zhan M, Johnson JK, Venezia RA, Harris AD, Roghmann M. Comparison of the methicillin-resistant Staphylococcus aureus acquisition among rehabilitation and nursing home residents. Infect Control and Hosp Epidemiol. 2011;32(3): Harris AD, Johnson JK, Thom KA, Morgan DJ, McGregor JC, Ajao AO, Moore AC, Comer AC, Furuno JP. Risk factors for Development of Intestinal Colonization with Imipenem-resistant Pseudomonas aeruginosa in the Intensive Care Unit Setting. Infect Control and Hosp Epidemiol. 2011;32(7): Barnes SL, Harris AD, Golden BL, Wasil EA, Furuno JP. Contribution of Inter-Facility Patient Movement to Overall MRSA Prevalence Levels. Infect Control and Hosp Epidemiol. 2011;32(11): Furuno JP, Krein S, Lansing B, Mody L. Healthcare worker opinions on the use of contact isolation precautions in long-term care facilities. Am J Infect Control. 2012; 40(3):263-6

5 J.P. Furuno, page 3 February Furuno JP, Johnson JK, Schweizer ML, Uche A, Stine OC, Shurland SM, Forrest GN. Community-associated Methicillin-resistant Staphylococcus aureus Bacteremia and Endocarditis among HIV Patients: a cohort study. BMC Infect Dis. 2011;11: Emerson CB, Eyzaguirre ML, Albrecht JS, Comer AC, Harris AD, Furuno JP. Healthcareassociated infection and Hospital Readmission. Infect Control Hosp Epidemiol.2012;33(6): Albrecht JS, Hirshon JM, Goldberg R, Langenberg P, Day HR, Morgan DJ, Comer AC, Harris AD, Furuno JP. Serious Mental Illness and Acute Hospital Readmission in Diabetic Patients. Am J Med Qual. 27(6): Ajao AO, Johnson JK, Harris AD MPH, Zhan M, McGregor JC, Thom KA, Furuno JP. Risk of acquiring extended spectrum β-lactamase producing Klebsiella species and Escherichia coli from prior room occupants in the intensive care unit. Infect Control Hosp Epidemiol.201;34(5): Albrecht JS, Gruber-Baldini AL, Fromme EK, McGregor JC, Lee DSH, Furuno JP. Quality of Hospice Care for Patients with Dementia. J Am Geriatr Soc. 2013;61(7): Albrecht JS, McGregor JC, Fromme EK, Bearden DT, Furuno JP. A Nationwide Analysis of Antibiotic Use in Hospice Care in the Final Week of Life. J Pain Symptom Manage. 2013;46(4): Rosenberg JH, Albrecht JS, Fromme EK, Noble, BN, McGregor JC, Comer AC, Furuno JP. Antimicrobial Use for Symptom Management in Patients Receiving Hospice and Palliative Care: A Systematic Review. J Palliat Med. 2013;16(12): Hirshon JM, Comer AC, Rosenberg JH, Johnson JK, Moore SL, MacKenzie TD, Hall KK, Furuno JP. Methodological Challenges Associated with Developing and Implementing Antibiograms in Nursing Homes. Infect Control Hosp Epidemiol. (in press) 14. Pfeiffer CD, Cunningham MC, Poissant T, Furuno JP, Townes JM, Leitz A, Thomas A, Buser GL, Arao RF, Beldavs ZG. Establishment of a Statewide Network for Carbapenem-Resistant Enterobacteriaceae Prevention in a Low Incidence Region. Infect Control Hosp Epidemiol. (in press) 15. Albrecht JS, Gruber-Baldini AL, Hirshon JM, Brown CH, Goldberg R, Rosenberg JH, Comer AC, Furuno JP. Depressive Symptoms and Hospital Readmission in Older Adults. J Am Geriatr Soc. (in press) Selected Invited Presentations (Within Past 5 years) Regional 5/2012 Invited Speaker The Role of Environmental Cleaning in Preventing HAIs HAI Regional Training Program- Region 10 Olympia, WA 5/2012 Invited Speaker Preventing Catheter-Associated Urinary Tract Infections (CAUTI) HAI Regional Training Program- Region 10 Olympia, WA

6 J.P. Furuno, page 4 February /2012 Invited Speaker Antibiotic Use in Hospice and Palliative Care 2012 Oregon Statewide Palliative Care Conference Portland, OR 3/2013 Invited Speaker Infection Control & Multiple Drug Resistant Organisms (MDROs) 2013 Oregon Healthcare Association (OHCA) Spring Expo Grand Ronde, OR 4/2013 Invited Speaker Battling Superbugs: Infection Control and Multiple Drug Resistant Organisms (MDROs) in Long-term Care LeadingAge Health Advisory Webinar Portland, OR 4/2014 Invited Speaker Pearls of Publishing in the Pharmacy Literature Oregon Society of Health System Pharmacists Gleneden Beach, OR 5/2014 Invited Speaker Antibiotic Use in Hospice Care 24 th Annual Statewide (Ethics) Conference Bend, OR National 11/2009 Invited Speaker "Epidemiologic Methods to Combat Hospital-acquired Infections and Antimicrobial Resistance" Fairleigh Dickinson University, Department of Biological Sciences Seminar Series Madison, NJ. 4/2011 Invited Speaker Managing the Continuum of Care: Implications of MDRO Movement between Acute and Non-acute care Facilities Society for Healthcare Epidemiology of America (SHEA) 2011 Annual Scientific Meeting. Dallas, TX.

7

8

9 DEPARTMENT OF EPIDEMIOLOGY AND PREVENTIVE MEDICINE DIVISION OF HEALTHCARE OUTCOMES RESEARCH UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE March 6, 2014 To the Selection Committee, RE: OHSU Research Award Please accept this letter of the strongest support for Dr. Jon Furuno for the OHSU Research Award. I have known Dr. Furuno for over 12 years and can confidently attest to the outstanding quality of his research and importance of the questions he has chosen to address. Dr. Furuno s research aims to improve infection control and antibiotic prescribing strategies in older adults. As an infectious disease physician and researcher and the President-Elect of the Society for Healthcare Epidemiology (SHEA) of America, I am well aware of the need for evidence to support current practices in this vulnerable patient population. Dr. Furuno has been a leader in this area for several years. He has received two federal awards (NIH and AHRQ) to support his work in this area totally funding in excess of one million dollars. He has also published 75 papers, many in prestigious medical journals, and given many invited local, regional, and national presentations on infectious diseases issues in older adults. Dr. Furuno is also an active member of the SHEA Long-term Care Special Interest group and serves on SHEA s Public Policy and Government Affairs Committee and the editorial board of Infection Control and Hospital Epidemiology. Dr. Furuno has now turned his attention towards improving antibiotic prescribing and overall healthcare quality in hospice patients. Although I am less familiar with this work, I have no doubt that Dr. Furuno will be highly successful in this area as well. As his CV suggests, he has already published several papers on hospice care, received one grant award with two others under review, and is the Chairelect of the Research Special Interest Group of the American Academy of Hospice and Palliative Medicine. This productivity and his obtaining a leadership role in a national organization after only two years of work in a content area, speak to Dr. Furuno s outstanding work ethic and the respect he garners from his peers. Lastly, it is not only the quality and importance of Dr. Furuno s research that separates him from his peers, but the method in which he conducts himself. During his time at the University of Maryland, Dr. Furuno was known for being the ultimate team player; someone would readily contribute on any level to support to overall goals of the project. Although he has transitioned into primarily a leadership role in his current work, I am sure he carries the same attitude and sets a wonderful example for colleagues and trainees. In close, I cannot recommend Dr. Furuno more strongly for the OHSU Research Award. 100 N Greene Street, Lower Level Baltimore, MD fax

10 Sincerely, Anthony Harris, MD, MPH Head Division of Genomic Epidemiology and Clinical Outcomes Department of Epidemiology and Public Healthreventive Medicine Professor University of Maryland Hospital Epidemiologist University of Maryland Medical Center Phone: Fax: N Greene Street, Lower Level Baltimore, MD fax